Agitation in Alzheimer's disease is a clinically important syndrome characterized by excessive motor activity, verbal aggression, physical aggression, emotional distress, or resistance to care that exceeds what would be expected from unmet basic needs alone. [1][2] It is associated with caregiver burden, faster institutionalization, higher injury risk, and more frequent use of psychotropic medication. [1:1][3]
Agitation affects approximately 40-60% of individuals with Alzheimer's disease over the course of their illness. [4] Several factors increase the risk of developing agitation:
Common manifestations include restlessness, pacing, irritability, shouting, aggression, nighttime disruption, and distress during personal care. Symptoms often worsen with pain, infection, sleep disruption, sensory overload, or environmental change. [1:3][2:1]
Agitation typically presents in moderate to advanced stages of Alzheimer's disease, though it can emerge at any point in the disease trajectory. The behavioral disturbances are often categorized into three domains: physical aggression, non-aggressive agitation, and verbal agitation. [4:2]
The neurobiological basis of agitation in Alzheimer's disease involves multiple overlapping mechanisms:
Several validated instruments help assess agitation severity:
First-line approaches include: [6]
When non-drug approaches are insufficient, medications may be considered:
Important considerations: Antipsychotics carry FDA black box warnings for increased mortality in dementia patients. Benefits must be carefully weighed against risks, with lowest effective doses and regular reassessment. [7:3]
Brexpiprazole (Rexulti) became the first FDA-approved drug specifically labeled for agitation associated with dementia due to Alzheimer's disease in 2023. [3:3][7:4] This represents a significant milestone, as previous treatments were used off-label with limited evidence and substantial risks.
Non-drug strategies remain foundational, especially for identifying triggers and reducing recurrent behavioral escalation. [1:4][2:3] A personalized, multimodal approach addressing medical, environmental, and psychosocial factors yields the best outcomes.
Agitation significantly impacts caregivers, contributing to:
Healthcare systems should integrate caregiver support with treatment plans, providing education, respite resources, and access to behavioral specialists.
Emerging areas of investigation include:
Neuropsychiatric Symptoms in Patients With Pathologically Confirmed Comorbid Alzheimer Disease and Frontotemporal Lobar Degeneration. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Agitation in Alzheimer's Disease as a Qualifying Condition for Medical Cannabis in the United States: A Brief Report on Current Trends. The American Journal of Geriatric Psychiatry. 2026. ↩︎ ↩︎ ↩︎ ↩︎
AI-Based Social Assistive Robots in Dementia Care: A Systematic Review and Meta-Analysis. The Gerontologist. 2026. ↩︎ ↩︎ ↩︎ ↩︎
Tools to Measure Noncognitive Symptoms in Nursing Home Residents With Advanced Dementia: A Scoping Review. Journal of the American Medical Directors Association. 2026. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Early Behavioral and Cognitive Changes in Patients With Pathologically Confirmed Alzheimer Disease, Lewy Body Dementia, and Mixed Dementia. Neurology Open Access. 2026. ↩︎ ↩︎
Non-pharmacological interventions for agitation in dementia: A systematic review. International Journal of Geriatric Psychiatry. 2024. ↩︎
Brexpiprazole for agitation in Alzheimer's disease: From clinical trials to real-world practice. Expert Opinion on Pharmacotherapy. 2024. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎